These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23472088)

  • 21. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages.
    Whittle HC; Maine N; Pilkington J; Mendy M; Fortuin M; Bunn J; Allison L; Howard C; Hall A
    Lancet; 1995 Apr; 345(8957):1089-92. PubMed ID: 7715343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer.
    Akbar SM; Furukawa S; Hasebe A; Horiike N; Michitaka K; Onji M
    Int J Mol Med; 2004 Aug; 14(2):295-9. PubMed ID: 15254781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice.
    Wang Y; Chen K; Wu Z; Liu Y; Liu S; Zou Z; Chen SH; Qu C
    Int J Infect Dis; 2014 Dec; 29():31-6. PubMed ID: 25449231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp.
    Farag MM; Tedjokusumo R; Flechtenmacher C; Asen T; Stremmel W; Müller M; Protzer U; Weigand K
    Vaccine; 2012 Sep; 30(42):6034-9. PubMed ID: 22867720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells.
    Akbar SM; Abe M; Masumoto T; Horiike N; Onji M
    J Hepatol; 1999 May; 30(5):755-64. PubMed ID: 10365798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection.
    Lv S; Wang J; Dou S; Yang X; Ni X; Sun R; Tian Z; Wei H
    Hepatology; 2014 Feb; 59(2):385-94. PubMed ID: 23907803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice.
    Backes S; Jäger C; Dembek CJ; Kosinska AD; Bauer T; Stephan AS; Dišlers A; Mutwiri G; Busch DH; Babiuk LA; Gasteiger G; Protzer U
    Vaccine; 2016 Feb; 34(7):923-32. PubMed ID: 26776470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.
    Whitacre DC; Peters CJ; Sureau C; Nio K; Li F; Su L; Jones JE; Isogawa M; Sallberg M; Frelin L; Peterson DL; Milich DR
    Hum Vaccin Immunother; 2020; 16(2):251-268. PubMed ID: 31809638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overcoming tolerance in hepatitis B virus transgenic mice: a possible involvement of regulatory T cells.
    Roh S; Kim K
    Microbiol Immunol; 2003; 47(6):453-60. PubMed ID: 12906106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of humoral and cellular immune response to HBV vaccine can be up-regulated by STING ligand.
    Ito H; Kanbe A; Hara A; Ishikawa T
    Virology; 2019 May; 531():233-239. PubMed ID: 30928701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A fusion DNA vaccine encoding middle version of HBV envelope protein fused to interleukin-21 did not enhance HBV-specific immune response in mice.
    Zhang Y; Su WJ; Wang J; Bai XF; Huang CX; Lian JQ
    Viral Immunol; 2014 Nov; 27(9):430-7. PubMed ID: 25211639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a more efficient hepatitis B virus vaccine by targeting hepatitis B virus preS to dendritic cells.
    Jing M; Wang J; Zhu S; Ao F; Wang L; Han T; Yue X; Zhu Y; Ye L; Liu S
    Vaccine; 2016 Jan; 34(4):516-522. PubMed ID: 26686999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mushroom lectin enhanced immunogenicity of HBV DNA vaccine in C57BL/6 and HBsAg-transgenic mice.
    Gao W; Sun Y; Chen S; Zhang J; Kang J; Wang Y; Wang H; Xia G; Liu Q; Kang Y
    Vaccine; 2013 Apr; 31(18):2273-80. PubMed ID: 23499522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
    Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
    Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution of sex‑based immunological differences to the enhanced immune response in female mice following vaccination with hepatitis B vaccine.
    Li M; Zhao Y; Chen X; Fu X; Li W; Liu H; Dong Y; Liu C; Zhang X; Shen L; Li B; Tian Y
    Mol Med Rep; 2019 Jul; 20(1):103-110. PubMed ID: 31115567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody titration and immune response of Iranian beta-thalassemic patients to hepatitis B virus vaccine (booster effect).
    Azarkeivan A; Karimi G; Shaiegan M; Maghsudlu M; Tabbaroki A
    Pediatr Hematol Oncol; 2009 Jun; 26(4):195-201. PubMed ID: 19437322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV-transgenic mice.
    Qing Y; Chen M; Zhao J; Hu H; Xu H; Ling N; Peng M; Ren H
    Vaccine; 2010 Jun; 28(26):4301-7. PubMed ID: 20430121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice.
    Akbar SM; Kajino K; Tanimoto K; Kurose K; Masumoto T; Michitaka K; Horiike N; Onji M
    J Hepatol; 1997 Jan; 26(1):131-7. PubMed ID: 9148003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice.
    Oka Y; Akbar SM; Horiike N; Joko K; Onji M
    Immunology; 2001 May; 103(1):90-7. PubMed ID: 11380696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.